TY - JOUR AU - Higashiyama, Masahiko AU - Okami, Jiro AU - Maeda, Jun AU - Tokunaga, Toshiteru AU - Fujiwara, Ayako AU - Kodama, Ken AU - Imamura, Fumio AU - Kobayashi, Hisayuki PY - 2011 TI - Differences in chemosensitivity between primary and paired metastatic lung cancer tissues: In vitro analysis based on the collagen gel droplet embedded culture drug test (CD-DST) JF - Journal of Thoracic Disease; Vol 4, No 1 (February 01, 2012): Journal of Thoracic Disease Y2 - 2011 KW - N2 - Background: To elucidate the differences in chemosensitivity to anticancer drugs between primary and metastatic lesions in non-small cell lung cancer (NSCLC) patients, we examined the in vitro chemosensitivities of surgically resected NSCLC tissues. Methods: A total of 32 specimens were enrolled: 26 specimens of primary lesions paired with metastases in the lymph node, 3 specimens of primary lesions paired with metastases in the adrenal gland, and 3 specimens of primary lesions paired with metastases in the lung. The collagen gel droplet embedded culture drug test (CD-DST) was applied to examine the sensitivity of the tissues to anticancer drugs, including cisplatin, gemcitabine, vinorelbine, docetaxel and 5-fluorouracil. Results: The degree of in vitro sensitivity to each anticancer drug varied between the primary and metastatic lesions. The sensitivity of the paired metastatic lesions was significantly lower than that of the primary lesions only for gemcitabine ( P =0.029), vinorelbine ( P =0.012), and docetaxel ( P =0.009). The incidence of cases diagnosed as CD-DST-sensitive among the paired metastatic lesions was significantly lower than that for the primary lesions for vinorelbine ( P =0.035) or docetaxel ( P =0.022). The difference in the sensitivity to gemcitabine between the primary and paired non-lymphatic metastases was clearer than that between the primary lesion and paired lymph node metastases. Conclusions: The sensitivities of the paired metastatic lesions to some anticancer drugs were significantly lower than those of the primary lesions. When performing chemotherapy based on CD-DST data using primary tumors from patients with postoperative recurrence, an appropriate regimen can be selected by carefully considering these differences. UR - https://jtd.amegroups.org/article/view/195